Skip to main content
Log in

Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

We used the method of alkaline elution to compare quantitatively the DNA lesions produced by cisplatin and carboplatin in the AKR leukemia in vivo. These data were compared with cytotoxicity of each drug in the same animal model and in a solid tumor murine model (colon 26).

DNA-protein and DNA-DNA interstrand crosslinks were formed in similar proportions by both drugs when peak values of crosslinking were compared. No clear difference in the rate of formation of both types of crosslinks could be observed between these drugs.

On a molar basis a 3- to 4-fold more carboplatin had to be given to obtain equivalent frequencies of both types of crosslinks. In contrast, to obtain equitoxicity in the same animal tumor model, 13 fold higher doses of carboplatin had to be given. This difference in cytotoxicity between both drugs is comparable to the difference measured in colon 26 in vivo (16 fold). Both values are in the range of literature data (10–25 fold) dealing with the relative potency of cisplatin and carboplatin in murine tumor models.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

DIC:

DNA-DNA Interstrand Crosslinks

DPC:

Protein-DNA Crosslinks

EDTA:

Ethylene-Diammine-Tetra-Acetic Acid

PK:

Proteinase K

PSA:

Puck's Saline A

SSB:

Single Strand Breaks

ILS:

Increase in Life Span

Carboplatin-Cis-(diammino)(1,1-cyclobutane-dicarboxylato)-Platinum (II), Cisplatin:

Cis-Diamminedichloroplatinum (II)

References

  1. Evans BD, Raju KS, Calver AH, Harland SJ, Wiltshaw E: Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep 67:997–1000, 1983

    Google Scholar 

  2. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Sem Oncol 11:251–263, 1984

    Google Scholar 

  3. Borch RF: The platinum anti-tumor drugs. In: Powis G, Prough RA (eds) Metabolism and Action of Anti-Cancer Drugs. Taylor and Francis, London, New York and Philadelphia, 1987, pp 163–193

    Google Scholar 

  4. Cardonna JP, Lippard SJ: Chemical and Biological Studies of Cis-diamminedichloroplatinum (II) Binding to DNA. In: Platinum Coordination Complexes in Cancer Chemotherapy. Hacker MP, Douple EB, Krakoss IH (eds). Martinus Nijhoff Publishing, Boston, 1984, pp 14–25

    Google Scholar 

  5. Zwelling LA, Anderson T, Kohn KW: DNA-Protein and DNA-interstrand cross-linking by cis- and trans-platinum (II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39:365–369, 1979

    Google Scholar 

  6. Bodenner DL, Dedon PC, Keng PC, Borch RF: Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum (II)-induced cytotoxicity, DNA cross-linking, and γ-glutamyltranspeptidase inhibition. Cancer Res 46:2745–2750, 1986

    Google Scholar 

  7. Bodenner DL, Dedon PC, Keng PC, Borch RF: Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate rescue. Cancer Res 46:2751–2756, 1986

    Google Scholar 

  8. Laurent G, Erickson LC, Sharkey NA, Kohn KW: DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum (II) in human normal and tumor cell lines. Cancer Res 41:3347–3351, 1981

    Google Scholar 

  9. Zwelling LA, Michaels S, Schwartz H, Dobson PP, Kohn KW: DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res 41:640–649, 1981

    Google Scholar 

  10. Micetich KC, Barnes D, Erickson LC: A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum (II) and cisdiamminidichloroplatinum (II) on L1210 cells. Cancer Res 45:4043–447, 1985

    Google Scholar 

  11. Corbett TH, Griswold Jr. DP, Roberts BJ, Peckham JC, Schabel Jr. FM: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35:2434–2439, 1975

    Google Scholar 

  12. Corbett TH, Griswold Jr. DP, Roberts BJ, Peckham JC, Schabel Jr. FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660–2680, 1977

    Google Scholar 

  13. Kohn KW: DNA as target in cancer chemotherapy: Measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Methods in Cancer Res 16:291–345, 1979

    Google Scholar 

  14. Meyn RE, Jenkins WT: Variation in normal and tumor tissue sensitivity of mice to ionizing radiation-induced DNA strand breaks in vivo. Cancer Res 43:5668–5673, 1983

    Google Scholar 

  15. Cesarone CF, Bolognesi C, Santi L: Improved microfluorometric DNA determination in biological material using 33258 Hoechst. J Biochem 100:188–197, 1979

    Google Scholar 

  16. Kohn KW, Ewig RAG, Erickson LG, Zwelling LA: Measurement of strand breaks and cross-linking by alkaline elution. In: Friedberg EC, Hanawalt PC (eds) DNA Repair: A Laboratory Manual of Research Procedures, Vol. 1, Part B, Marcel Dekker, Inc., pp 379–401, 1981

  17. DeNeve WJ, Everett CK, Suminski JE, Valeriote FA: Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 48:6002–6005, 1988

    Google Scholar 

  18. Ferguson GA: Statistical Analysis in Psychology and Education. 5th Edition, McGraw and Hill, New York, 1981

    Google Scholar 

  19. Rahman A, Kyung Roh J, Wolpert-DeFilippes MK, Goldin A, Venditti JM, Woolley PV: Therapeutic and pharmacological studies of tetrachloro-(d, 1-trans)1,2-diamminocyclohexane platinum (IV) (Tetraplatin), a new platinum analogue. Cancer Res 48:1745–1752, 1988

    Google Scholar 

  20. Terreggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, DenEngelse L: Immunocytochemical detection of interaction products of cis-(diammino)-(1,1-cyclobutanedicarboxylate) platinum (II) with DNA in rodent tissue sections. Cancer Res 47:6719–6725, 1987

    Google Scholar 

  21. Gaver RC, George AM, Deeb G: In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin. Cancer Chemother Pharmacol 20:271–276, 1987

    Google Scholar 

  22. Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanisms of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloro-platinum (II) and cis-diammine(1,1-cyclobutanedicarboxylate) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972–1979, 1986

    Google Scholar 

  23. Roberts JJ, Friedlos F: Quantitative estimation of cisplatininduced DNA interstrand cross-links and their repair in mammalian cells: Relationship to toxicity. Pharmac Ther 34:215–246, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by an award from the Belgian Work against Cancer.

American Cancer Society Cancer Development Award Recipient.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeNeve, W., Valeriote, F., Tapazoglou, E. et al. Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo . Invest New Drugs 8, 17–24 (1990). https://doi.org/10.1007/BF00216920

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00216920

Key words

Navigation